Cách Quản Lý Bệnh Nhân HCV Trên Thẩm Phân Máu?

Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998;53(4):1022–5. Fissell R, Bragg-Gresham J, Woods J, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335–42. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009;150:33–9. Sauné K, Kamar N, Miédouqé M, Weclawiak H, Dubois M, Izopet J, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26:2309–16. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol. 2011;55(2):474–82. Kamar N, Alric L, Izopet J, Rostaing L. Hepatitis C virus and kidney disease. Clin Res Hepatol Gatroenterol. 2013;37:328–33. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;109:S1–S99. Goodkin D, Bragg-Gresham J, Koenig G, Wolfe RA, Akiba T, Andreucci VE, et al. Association of comorbid conditions and mortality in haemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns. J Am Soc Nephrol. 2003;14:3270–7. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19:601–7. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236. The recent and complete recommendations with new DAAs for the treatment of HCV infection in both general and special population. Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol. 2013;37:340–6. Su F-H, Su CT, Chang SN, Chen PC, Sung FC, Lin CC, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553–60. This work argues that HCV chronic infection increases the risk of renal disease, of end-stage renal disease (ESRD) and of ESRD-related mortality, which is a major issue to indicate antiviral treatment in dialysis patient. Lee MH, Yang HI, Lu SN, Jen CL, You SL, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469–77. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive hemodialysis patients: a population based study. Nephrol Dial Transplant. 2005;20(8):1662–9. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Tranplantation. 2005;80:1550–5. Canbakan M, Senturk H, Canbakan B, Toptas T, Tabak O, et al. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C. Nephron Clin Pract. 2011;117(3):c289–295. Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, et al. Can aminotransferase to platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients ? Nephrol Dial Transplant. 2014;29:1247–52. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6(5):1057–65. Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, et al. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transplant Int. 2009;22(5):568–73. Jadoul M, Horsmans Y. Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. Nephrol Dial Transplant. 2014;29:1108–10. Pol S, Carnot F, Bedossa P, Nalspas B, Lagneau JL, Fontaine H, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107–12. EASL. Clinical practice guidelines: management of hepatitis C infection. J Hepatol. 2011;55:245–64. Pol S. Hepatitis C, virus: 25 years-old, the end ? Med Sci (Paris). 2013;29(11):998–1003. Pol S, Corouge M, Sogni P. Oral viral antiviral therapies for chronic hepatitis C infection. Ther Adv Infect Dis. 2013;1(3):107–16. KDIGO. Clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant. 2009;9(S3):S52–57. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78(5):745–50. Cosconea S, Fontaine H, Meritet JF, Corouge M, Sogni P, et al. Benefits associated with antiviral treatment in kidney allograft recipients with hepatitis B chronic infection. J Hepatol. 2012;57(1):55–60. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38(5):405–12. Roth D, Nelson D, Burchfeld A, Liapakis A, Silva M, et al. C-SURFER: Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. EASL 2015. J Hepatol 2015; 62(2): S263 and Lancet 2015 in press. This is the first trial of grazoprevir and elbasvir combination in dialysis patients showing high SVR and good tolerance. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, et al. Safety of ombitasvir/paritaprevir/ritonavir + dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. EASL 2015. J Hepatol. 2015;62(S2):S257. Gane EJ, Robson RA, Bonacini M, Maliakkal B, Liu L, et al. Safety, and anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. AASLD 2014. Hepatology. 2014; 60: Abstract 133A. Saxena V, Koraishy FM, Sise M, Kim JK, Chung RT, Liapakis A, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-target. EASL 2015. J Hepatol. 2015;62(S2):S267. Nazario HE, Ndungu M, Modi A. Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients in end-stage renal disease or GFR < 30mL/min. EASL 2015. J Hepatol. 2015;62(S2):S635. Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, et al. Safety, efficacy and tolerability of half-dose sofosbuvir and simeprevir treatment of hepatitis C in patients with end-stage renal disease. EASL 2015. J Hepatol. 2015;63(3):763–5. Half dose Sofosbuvir and full dose Simeprevir combination is safe and reaches high SVR in dialysis patients. Czul F, Schiff E, Peyton A, Levy C, Hernandez M, et al. First ribavirin-free sofosbuvir and simeprevir treatment of hepatitis C genotype 1 patients with severe renal impairment (GFR < 30 mL/min or dialysis) EASL 2015. J Hepatol. 2015;62(S2):S670–1. Desnoyer A, et al. Sofosbuvir in hemodialysis 400 mg daily or only the day of hemodialysis ? Oral abstract presented at the 16 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 28 May 2015, Whashington DC, USA. Jadoul M, Horsmans Y. Towards eradication of the hepatitis C virus from dialysis units? Lancet 2015.